

Michael T Schweizer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5033760/publications.pdf>

Version: 2024-02-01

51
papers

2,002
citations

331670

21
h-index

276875

41
g-index

54
all docs

54
docs citations

54
times ranked

3026
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. <i>Science Translational Medicine</i> , 2015, 7, 269ra2.	12.4	205
2	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. <i>Lancet Oncology</i> , The, 2018, 19, 76-86.	10.7	149
3	MSH2 Loss in Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6863-6874.	7.0	122
4	Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. <i>European Urology</i> , 2019, 76, 452-458.	1.9	109
5	Microsatellite instability in prostate cancer by PCR or next-generation sequencing. , 2018, 6, 29.		96
6	Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. <i>JAMA Oncology</i> , 2021, 7, 107.	7.1	90
7	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. <i>PLoS ONE</i> , 2018, 13, e0198389.	2.5	86
8	Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. <i>Prostate</i> , 2014, 74, 1278-1285.	2.3	84
9	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1371-1382.	1.6	65
10	Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. <i>Oncotarget</i> , 2016, 7, 82504-82510.	1.8	64
11	Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study. <i>Prostate</i> , 2016, 76, 1218-1226.	2.3	63
12	Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. <i>PLoS ONE</i> , 2020, 15, e0233260.	2.5	63
13	Persistent androgen receptor addiction in castration-resistant prostate cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 128.	17.0	59
14	Immunotherapy for prostate cancer: recent developments and future challenges. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 641-655.	5.9	53
15	CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020, 4, 382-392.	3.0	51
16	A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. <i>Stem Cells Translational Medicine</i> , 2019, 8, 441-449.	3.3	50
17	AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. <i>Cancers</i> , 2017, 9, 7.	3.7	49
18	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. <i>European Urology</i> , 2021, 79, 692-699.	1.9	49

#	ARTICLE	IF	CITATIONS
19	Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. <i>European Urology</i> , 2020, 77, 144-155.	1.9	46
20	Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016, 33, 44.	2.5	40
21	Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA. <i>JAMA Oncology</i> , 2021, 7, 1378.	7.1	40
22	Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e855-e857.	1.9	26
23	A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling. <i>Prostate</i> , 2016, 76, 1303-1311.	2.3	21
24	Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 785-795.	0.3	19
25	Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. <i>Prostate</i> , 2019, 79, 701-708.	2.3	18
26	Liquid biopsy: Clues on prostate cancer drug resistance. <i>Science Translational Medicine</i> , 2015, 7, 312fs45.	12.4	17
27	Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes. <i>Bladder Cancer</i> , 2020, 6, 71-81.	0.4	16
28	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 388-396.	3.9	15
29	Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. <i>JCI Insight</i> , 2021, 6, .	5.0	15
30	Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2015, 75, 1814-1820.	2.3	14
31	Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 72, 323-325.	1.9	14
32	Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2020, 38, 3740-3742.	1.6	14
33	Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 144-154.	1.9	13
34	Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6001-6011.	7.0	13
35	Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016, 33, 77.	2.5	11
36	Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2021, 27, 6662-6665.	7.0	11

#	ARTICLE	IF	CITATIONS
37	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline <i>ATM</i> versus <i>BRCA2</i> mutations. <i>Prostate</i> , 2021, 81, 1382-1389.	2.3	10
38	A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer. <i>Advances in Therapy</i> , 2020, 37, 4910-4929.	2.9	9
39	Mismatch repair deficiency and clinical implications in prostate cancer. <i>Prostate</i> , 2022, 82, .	2.3	9
40	Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. <i>Prostate</i> , 2021, 81, 418-426.	2.3	8
41	Targeting intratumoral androgens: statins and beyond. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 388-395.	3.2	7
42	Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0239686.	2.5	6
43	<i>BRCA2</i> Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series. <i>JCO Precision Oncology</i> , 2022, , .	3.0	6
44	“Matching the Mismatch Repair” Deficient Prostate Cancer with Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 981-983.	7.0	5
45	Metastatic Adenocarcinoma of the Epididymis: A Case Report and Brief Literature Review. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e335-e338.	1.9	4
46	Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. <i>European Urology Open Science</i> , 2022, 41, 112-115.	0.4	4
47	Hormone levels following surgical and medical castration: defining optimal androgen suppression. <i>Asian Journal of Andrology</i> , 2018, 20, 405.	1.6	3
48	In Reply to the Letter to the Editor from Raj et al.: Clinical Evidence Indicates Allogeneic Mesenchymal Stem Cells Do Not Pose a Significant Risk for Cancer Progression in the Context of Cell-Based Drug Delivery. <i>Stem Cells Translational Medicine</i> , 2019, 8, 739-740.	3.3	1
49	Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 496.e1-496.e8.	1.6	1
50	Response: letter to the editor. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 229-229.	3.4	0
51	Multimodality Treatment of Bilateral Wilms Tumor in a Pregnant Female. <i>Urology</i> , 2020, 136, e42-e44.	1.0	0